Additionally, studying the efficacy and mechanisms of SGLT-2 inhibitors in patients with specific kidney diseases, such as polycystic kidney disease and autoimmune nephritis, is an important direction for future research (158). Here, SLC5A2 is linked to polycystic kidney disease.